Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 588

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 6
Chunk 588
---
 be issued upon exercise of all options granted may not in the aggregate exceed 5% of our shares outstanding on April 27, 2020. Share awards under our LTIP may not exceed 5% of our shares outstanding on the adoption date of our LTIP.
Outstanding Awards and Grants of Awards
Share options outstanding and grants made in 2024 under the 2015 Option Scheme
As of December 31, 2024, options to purchase an aggregate of 29,640,273 ordinary shares, representing approximately 3.4% of our outstanding share capital, at a weighted average exercise price of £3.55 ($4.47) per ordinary share and an expiration date of 10 years from the respective date of grant remained outstanding under the 2015 Option Scheme. In the year ended December 31, 2024, we granted options to purchase an aggregate of 2,965,328 ordinary shares, representing approximately 0.3% of our outstanding share capital, at an exercise price of £2.93 ($3.69) per ordinary share under the 2015 Option Scheme. For the share options granted to Dr. Weiguo Su in 2024, the exercise of the share options is conditional upon the fulfilment of certain performance targets relating to the Group over the financial year of 2023 to 2025 and 2024 to 2026. Vesting will occur two business days after the date of announcement of the annual results of the Company for the financial years ending December 31, 2025 and 2026. The other options vest in equal instalments of 25% over a four-year period.
​

Grants and vesting of LTIPs
In the year ended December 31, 2024, we granted performance based awards under our LTIP to two of our executive directors and 133 employees, giving them a conditional right to receive ordinary shares to be purchased by the third-party trustee up to an aggregate maximum cash amount of $19,304,017. These awards are related to the achievement of performance targets and will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026. For additional information on LTIP awards held by our executive officers, please see “B. Compensation—Executive Officer Compensation—Long-Term Incentive Compensation.” For additional information on LTIP awards to our directors, please see “B. Compensation—